Literature DB >> 3121800

Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

T L Perry1, V W Yong, S Hansen, K Jones, C Bergeron, J G Foulks, J M Wright.   

Abstract

Idiopathic Parkinson's disease (PD) may possibly be caused by one or more unidentified neurotoxins present in the environment, or formed endogenously, which progressively damage dopaminergic nigrostriatal neurons. N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is an experimental neurotoxin which produces biochemical and neuropathological changes in humans, lower primates and mice that closely resemble those found in PD. Because the mechanisms of neuronal damage in both idiopathic PD and in the MPTP model of PD may involve free radical formation in the substantia nigra, antioxidants might protect dopaminergic neurons. Previously, we found that both alpha-tocopherol and beta-carotene partially protected mice against MPTP. However, in the experiments described in this paper, neither alpha-tocopherol nor beta-carotene, each administered in massive doses, had any demonstrable protective effect for dopaminergic nigrostriatal neurons in marmosets injected with low doses of MPTP. Without more knowledge about the identity of the neurotoxin(s) causing idiopathic PD, and their mechanism of action, it is not possible at this time to predict whether these 2 antioxidants might be clinically useful in preventing or ameliorating PD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121800     DOI: 10.1016/0022-510x(87)90106-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  Natural antioxidants for neurodegenerative diseases.

Authors:  Baolu Zhao
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

2.  Effect of vitamin E deficiency on rat brain monoamine metabolism.

Authors:  K Adachi; M Izumi; T Mitsuma
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

3.  Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease.

Authors:  J A Molina; F de Bustos; F J Jiménez-Jiménez; J Benito-León; M Ortí-Pareja; T Gasalla; A Tallón-Barranco; J A Navarro; J Arenas; R Enríquez-de-Salamanca
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 4.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 5.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

6.  Cruciferous nutraceutical 3H-1,2-dithiole-3-thione protects human primary astrocytes against neurocytotoxicity elicited by MPTP, MPP(+), 6-OHDA, HNE and acrolein.

Authors:  Zhenquan Jia; Hong Zhu; Yunbo Li; Hara P Misra
Journal:  Neurochem Res       Date:  2009-05-01       Impact factor: 3.996

7.  Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease.

Authors:  D King; J R Playfer; N B Roberts
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

8.  The promise of neuroprotective agents in Parkinson's disease.

Authors:  Stacey E Seidl; Judith A Potashkin
Journal:  Front Neurol       Date:  2011-11-21       Impact factor: 4.003

Review 9.  The emerging role of nutrition in Parkinson's disease.

Authors:  Stacey E Seidl; Jose A Santiago; Hope Bilyk; Judith A Potashkin
Journal:  Front Aging Neurosci       Date:  2014-03-07       Impact factor: 5.750

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.